Fairfield Bush & CO. boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 17.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 20,855 shares of the biopharmaceutical company’s stock after acquiring an additional 3,059 shares during the quarter. Fairfield Bush & CO.’s holdings in Bristol-Myers Squibb were worth $1,278,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Delphi Private Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $108,000. Massey Quick Simon & CO. LLC raised its stake in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares during the last quarter. NuWave Investment Management LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter valued at about $119,000. Horan Capital Advisors LLC. purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at about $122,000. Finally, AllSquare Wealth Management LLC purchased a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at about $134,000. 71.53% of the stock is owned by institutional investors.
Shares of Bristol-Myers Squibb stock opened at $58.65 on Monday. Bristol-Myers Squibb has a twelve month low of $51.56 and a twelve month high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $96,061.19, a P/E ratio of 19.49, a price-to-earnings-growth ratio of 1.53 and a beta of 0.96.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 annualized dividend and a yield of 2.73%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 53.16%.
A number of equities analysts have weighed in on the company. Jefferies Group reiterated a “hold” rating and set a $66.00 price objective on shares of Bristol-Myers Squibb in a research note on Friday. ValuEngine lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Vetr upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating and set a $60.72 price target for the company in a research note on Thursday, February 1st. Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Monday, January 22nd. Finally, DZ Bank lowered Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $66.45.
WARNING: This article was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.chaffeybreeze.com/2018/04/16/fairfield-bush-co-raises-holdings-in-bristol-myers-squibb-bmy.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.